GT Biopharma is trading at $5.80, down 6.45%, alongside biotech-sector weakness; no direct cause is confirmed.
- XBI is down 2.04%. Broader risk-off conditions include geopolitical and rate concerns, but these are context, not confirmed direct causes.
- The company’s press-release listing shows no announcement dated October 8; its latest listed release is from September 15.
- Live-session volume was not provided, so trading activity cannot be assessed.